Indazole-3-carboxylic acid derivative with anti-tumor activity, preparation method and application thereof
By synthesizing indazole-3-carboxylic acid derivatives, the problems of lag and high cost of existing small molecule antitumor drugs have been solved, and compounds with antitumor activity can be prepared under mild conditions, which are suitable for the preparation of antitumor drugs.
Patent Information
- Application Number
- CN202410373160.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-03-29
AI Technical Summary
Existing small molecule anti-tumor drugs suffer from delays and high medical costs, and there is a lack of effective drugs with independent intellectual property rights.
A 3-carboxylic acid derivative with antitumor activity was synthesized by nucleophilic addition, cleavage to remove the protecting group and amide reaction to prepare N-(3-(4-(trifluoromethyl)phenylurea)phenyl)-1H-indazole-3-carboxamide, and the introduction of a 3-fluoromethyl group to improve the drug properties.
The synthesis of novel urea compounds under mild conditions improves the lipid solubility, stability, and pharmacokinetic properties of drugs, making them suitable for the preparation of antitumor drugs and possessing broad application potential.
Smart Images

Figure CN118206490B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of pharmaceutical chemical synthesis technology, and in particular to an indazole-3-carboxylic acid derivative with anti-tumor activity, a preparation method and application thereof. Background Art
[0002] Cancer is an important factor endangering human health and has become the second leading cause of death in the world. With the emergence and widespread application of small molecule targeted anticancer drugs, the cure rate of cancer and the survival of patients have been significantly improved. Small molecule drugs refer to organic compounds with a molecular weight of less than 500 Daltons. They have excellent drug metabolism and tolerance and are easily taken up by tumor tissues, thereby exerting a therapeutic effect. In recent years, the application of small molecule drugs in tumor treatment has been continuously expanded. At present, many small molecule anticancer drugs have been approved for marketing, such as Gefitinib.
[0003] Although the application and research and development of small molecule anti-tumor drugs have achieved certain results, there are still a series of challenges and problems. First, the lag in marketing; second, the high cost of medicine. Therefore, it is urgent to develop small molecule anti-tumor drugs with good anti-tumor effects and independent intellectual property rights in China. Summary of the invention
[0004] The purpose of the present invention is to solve the deficiencies of the above-mentioned technology and provide an indazole-3-carboxylic acid derivative with anti-tumor activity, a preparation method and application thereof.
[0005] To this end, the present invention provides an indazole-3-carboxylic acid derivative having anti-tumor activity, wherein the structural formula of the indazole-3-carboxylic acid derivative is as follows:
[0006]
[0007] The present invention also provides a method for preparing the indazole-3-carboxylic acid derivative having anti-tumor activity, and the synthetic route thereof is as follows:
[0008]
[0009] in:
[0010] The name of compound 1 is tert-butyl (3-aminophenyl)carbamate;
[0011] The name of compound 2 is 1-isocyano-4-(trifluoromethyl)benzene;
[0012] Compound 3 is named tert-butyl (3-(3-(4-(trifluoromethyl)phenyl)ureido)phenyl)carbamate;
[0013] Compound 4 is named 1-(3-aminophenyl)-3-(4-(trifluoromethyl)phenyl)urea;
[0014] Compound 5 is named indazole-3-carboxylic acid;
[0015] The final target product, compound I, is named N-(3-(3-(4-(trifluoromethyl)phenyl)ureido)phenyl)-1H-indazole-3-carboxamide.
[0016] It includes the following steps:
[0017] (1) Compound 1 reacts with compound 2 in an organic solvent I under alkaline conditions with an organic base I. After the reaction is completed, compound 3 is obtained by a first post-treatment.
[0018] Reaction Mechanism: The reaction between the ketone group of compound 1 and the amino group of compound 2 is a nucleophilic addition reaction. In this reaction, the amino group attacks the carbonyl group of the ketone to form an intermediate. The intermediate is an amino ketone. After the intermediate is formed, an internal rearrangement occurs to form a new compound, namely compound 3; compound 3 is a kind of semicarbazide derivative. It should be noted that this reaction needs to be carried out under alkaline conditions, because semicarbazide is more susceptible to nucleophilic attack under alkaline conditions, and the carbonyl group of the ketone is also more susceptible to nucleophilic attack.
[0019] (2) Under acidic conditions, compound 3 is cleaved in organic solvent II to remove the boc group, and a white solid is produced. After a second post-treatment, compound 4 is obtained.
[0020] Reaction mechanism: Under acidic conditions, the protecting group Boc of compound-3 is released to form an amino side chain, and the protecting group Boc is removed to form compound 4.
[0021] (3) Compound 4 and Compound 5 are heated to react in an organic solvent III under the action of a polypeptide condensation reagent and an organic base II. After the reaction is completed, a third post-treatment is performed to obtain Compound I.
[0022] Reaction mechanism: The carboxyl group in the carboxylic acid molecule of compound 5 is protonated to generate a carboxyl ion. Then, the amino group in the aminoamide molecule of compound 4 accepts the proton of the carboxyl ion to generate a nitrogen ion. Next, the oxygen atom in the carboxyl ion attacks the nitrogen ion to form an ester bond in the amide. Finally, the intermediate of the amide is subjected to proton transfer and proton dissociation steps to obtain the final target product, compound I.
[0023] Among them, the final target product compound I contains CF3. In chemical drugs, the introduction of 3-fluoromethyl (-CF3) group is a common drug design strategy, mainly because the unique chemical and physical properties of fluorine atoms have an important influence on the biological activity, stability and pharmacokinetic properties of drug molecules. The 3-fluoromethyl group, especially due to its high electronegativity and small size, brings the following effects to drug molecules:
[0024] (1) Increased lipid solubility: The introduction of fluorine atoms can increase the lipid solubility of molecules, which helps to improve the ability of drugs to pass through biological membranes, thereby improving their bioavailability.
[0025] (2) Enhanced stability: The bond between the fluorine atom and the carbon atom is very stable. The introduction of a 3-fluoromethyl group can increase the metabolic stability of the compound, reduce rapid metabolism and degradation in the body, and thus prolong the duration of drug action.
[0026] (3) Influencing the binding of drugs to targets: Due to the high electronegativity of fluorine atoms, the introduction of 3-fluoromethyl groups can affect the electron distribution of the molecule, thereby affecting the binding affinity and selectivity of the drug to its target.
[0027] (4) Improving pharmacokinetic properties: The introduction of a 3-fluoromethyl group can change the absorption, distribution, metabolism, and excretion (ADME) properties of the drug, helping to optimize the overall pharmacokinetic profile of the drug.
[0028] (5) Increasing the acidity and alkalinity of the compound: The introduction of fluorine atoms can change the acidity and alkalinity of the molecule, which may affect the solubility and stability of the drug under different pH conditions.
[0029] In general, the introduction of 3-fluoromethyl groups is an important strategy in medicinal chemistry, which can significantly improve the efficacy and safety of drugs by improving their physicochemical properties and pharmacokinetic characteristics.
[0030] Preferably, in step (1), the organic solvent I is one of dichloromethane, ethyl acetate and isopropanol.
[0031] Preferably, the organic base I is one of triethylamine, methylbutylamide and pyridine.
[0032] Preferably, in step (1), the reaction temperature of compound 1 and compound 2 is 20 to 30°C.
[0033] Preferably, in step (1), the first post-treatment method is: evaporating the solvent, and controlling the heating temperature at 80-100° C. to remove the organic solvent I, the organic base I, the unreacted reactant compound 1 or compound 2, and the reaction product isocyanic acid to obtain compound 3.
[0034] Preferably, in step (2), the organic solvent II is one of 1,4-dioxane, dimethylformamide and tetrahydrofuran.
[0035] Preferably, in step (2), the acidic condition refers to one of hydrochloric acid, nitric acid and sulfuric acid.
[0036] Preferably, in step (2), the second post-treatment method is: collecting the solid by filtration and drying to obtain compound 4.
[0037] Preferably, in step (3), the organic solvent III is one of anhydrous N,N-dimethylformamide (hereinafter referred to as anhydrous DMF), dimethylacetamide, and dimethylpropionamide.
[0038] Preferably, in step (3), the polypeptide condensation reagent is one of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (hereinafter referred to as: HATU), benzotriazole-1-yl-oxytripyrrolidinophosphine hexafluorophosphate (hereinafter referred to as: PyBOP), and O-benzotriazole-tetramethyluronium hexafluorophosphate (hereinafter referred to as: HBTU).
[0039] Preferably, in step (3), the organic base II is one of triethylamine, pyridine, and hydroxylamine-2-methylpyridine.
[0040] Preferably, in step (3), compound 4 and a polypeptide condensation reagent are added to an organic solvent III, and after sufficient stirring to dissolve, compound 5 and an organic base II are added; the reaction temperature is controlled at 25 to 35° C. After the reaction is completed, a third post-treatment is performed to obtain compound I.
[0041] Preferably, in step (3), the third post-treatment method is: adding water at 0°C, filtering after solid precipitation, taking the filter cake and washing it with ethyl acrylate (hereinafter referred to as: EA) and water, and drying the filter cake after washing to obtain compound I.
[0042] The present invention also provides the use of the above-mentioned indazole-3-carboxylic acid derivatives with anti-tumor activity in the preparation of anti-tumor drugs.
[0043] The beneficial effects of the present invention are as follows: the present invention provides an indazole-3-carboxylic acid derivative with anti-tumor activity, a preparation method and an application thereof, wherein (3-aminophenyl)carbamic acid tert-butyl ester is used as a raw material, and N-(3-(3-(4-(trifluoromethyl)phenyl)ureido)phenyl)-1H-indazole-3-carboxamide is obtained through three steps of electrophilic addition, cleavage removal of the boc group and amide reaction. The urea compound containing the indazole group can complete the total synthesis of a new urea compound under relatively mild conditions, thereby providing feasibility for the subsequent large-scale production and marketization of the compound; the compound can be widely used in the preparation of anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:
[0045] Figure 1 The H NMR spectrum of the final target product Compound I prepared by the present invention;
[0046] Figure 2 The present invention is to identify the anti-tumor activity of the final target product compound I prepared by the present invention. DETAILED DESCRIPTION
[0047] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application clearer, the present application is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application. The methods used in the present invention are conventional methods unless otherwise specified; the raw materials and devices used are conventional commercial products unless otherwise specified.
[0048] Example 1
[0049] Compound 3 was prepared using the following synthetic route:
[0050]
[0051] Compound 1 (10 mmol, 2.08 g) and 2.2 g of triethylamine were dissolved in 50 mL of dichloromethane, and compound 2 (10 mmol, 1.87 g) was added. The mixture was reacted at 20 °C for 1 h, and then heated to 85 °C. The heating temperature was controlled at 80-100 °C, and the solvent was evaporated to obtain 3.48 g of compound 3.
[0052] Example 2
[0053] The synthetic route described in Example 1 was adopted, and the difference from Example 1 was that the reaction was carried out at 20°C for 1 hour. The other contents were the same as Example 1 and will not be repeated here, to obtain 3.36 g of compound 3.
[0054] Example 3
[0055] The synthetic route described in Example 1 was adopted, and the difference from Example 1 was that the reaction was carried out at 30°C for 1 hour. The other contents were the same as Example 1 and will not be repeated here, to obtain 3.31 g of compound 3.
[0056] Example 4
[0057] Compound 4 was prepared using the following synthetic route:
[0058]
[0059] The required amount of compound 3 was prepared by the synthetic route described in Example 1 and set aside. 3.9 g of compound 3 was dissolved in 50 mL of 1,4-dioxane, and 20 mL of 2M hydrochloric acid 1,4-dioxane solution was added to produce a white solid, which was directly filtered to obtain 2.8 g of compound 4.
[0060] Example 5
[0061] Compound 5 was prepared using the following synthetic route:
[0062]
[0063] 2.8 g of compound 4 and 5.7 g of HATU were dissolved in 10 mL of anhydrous DMF and stirred at 30 °C for 30 min. Then 1.6 g of compound 5 and 15 g of triethylamine were added and reacted at 70 °C for 4 h. TLC (DCM: MeOH = 20:1) was used to monitor the complete reaction of the raw materials. At 0 °C, 15 mL of distilled water was added, and solids were precipitated. The filter cake was filtered and washed with 5 mL of EA and water respectively. The filter cake was dried after washing with water to obtain 4 g of the final target product, compound I, with a yield of 94%.
[0064] Example 6
[0065] The synthetic route described in Example 5 was adopted, except that the reaction was carried out at 80° C. for 4 h. The other contents were the same as those in Example 5 and will not be described again. The final target product, 3.77 g of compound I, was obtained with a yield of 86%.
[0066] Example 7
[0067] The synthetic route described in Example 5 was adopted, which differed from the content of Example 5 in that the reaction was carried out at 60° C. for 4 h. The other contents were the same as those in Example 5 and were not described again. The final target product, 3.62 g of compound I, was obtained with a yield of 82%.
[0068] 1. Compound NMR identification:
[0069] The final target product compound I prepared by the present invention was subjected to nuclear magnetic resonance identification, wherein the nuclear magnetic hydrogen spectrum is as follows Figure 1 As shown, the parameters of H NMR spectrum are as follows:
[0070] 1H NMR (DMSO-d6, 400 MHz): δ 13.86 (s, 1H), 10.16 (s, 1H), 8.85 (s, 1H), 8.64 (s, 1H), 8.16 (d, J=8.4 Hz, 1H), 8.16 (s, 1H), 7.32-7.26 IR (neat): 3132, 2862, 1977, 1489, 1072, 1011, 802 cm -1 ;HRMS-ESI (m / z): calcd for C 22 H 16 F3N5O2[M+H] + 440.1334, found 440.1338. It can be seen that the structural formula of compound I is:
[0071]
[0072] , whose molecular formula is C 22 H 16 F3N5O2, with a molecular weight of 440.1338 Daltons, is an organic compound with a molecular weight below 500 Daltons and is a small molecule drug.
[0073] 2. Identification of anti-tumor activity
[0074] In this study, the antitumor activity of the target compounds was determined using six cell lines, namely Hela (human cervical cancer cells), Hep G2 (human liver cancer cells), HGC-27 (human gastric cancer cells (undifferentiated), A2780 (human ovarian cancer cells), A549 (human non-small cell lung cancer cells), and ACHN (human renal cell adenocarcinoma cells).
[0075] (1) Cell culture: Tumor cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS). 10 mL of complete culture medium was added to each 10 cm diameter culture dish and placed in a 37°C 5% CO2 cell culture incubator for culture.
[0076] (2) Cell passaging: When the cell density reaches 80%, discard the old culture medium and wash the cells twice with PBS, 10 mL each time. Add 1 mL of trypsin to digest the cells and observe under a microscope. When the cells become round, discard the trypsin and add a certain amount of fresh culture medium to blow the cells into single cells. Then divide the cell suspension into two and add them to two new 10 cm cell culture dishes. Finally, fill the culture medium to 10 mL. Place in a 37°C 5% CO2 cell culture incubator for culture.
[0077] (3) Cell freezing: Select cells with good growth status, discard the old culture medium, and wash the cells twice with PBS, 10 mL each time. Add 1 mL of trypsin to digest the cells and observe under a microscope. When the cells become round, discard the trypsin, add a certain amount of fresh culture medium, blow off the cells completely, and then add the cell suspension to a 15 mL centrifuge tube. Centrifuge horizontally at room temperature, 1000 rpm, 3 minutes. Resuspend the cells in the cell freezing solution prepared in advance, divide it into cryopreservation tubes with 1 mL per tube, place the cryopreservation tubes in a gradient cooling cryopreservation box, and place it in a -80℃ refrigerator. After 24 hours, transfer the cryopreservation tubes to a liquid nitrogen tank. All cell experiments need to be completed in a clean bench to ensure strict aseptic operation. The clean bench needs to be ultraviolet sterilized for more than 30 minutes before use.
[0078] (4) Cell number determination: Inoculate the cell suspension (100 μL / well) in a 96-well plate. Pre-incubate the plate in a humidified incubator (at 37°C, 5% CO2). Add 10 μL of CCK8 solution to each well of the plate. Be careful not to introduce bubbles into the wells as they will interfere with the OD reading. Incubate the plate in the incubator for 1-4 hours. Measure the absorbance at 450 nm using a microplate reader.
[0079] (5) Cell proliferation and cytotoxicity assay: Seed cells were cultured at 10 3 -10 4 The density of cells / well was cultured in 100 μL culture medium in a 96-well plate. The cells were cultured in a CO2 incubator at 37°C for 24 hours. 0 μM, 4 μM, 8 μM, 16 μM, 24 μM, and 32 μM of the final target product compound I of the present invention were added to a 96-well plate, and each concentration was repeated in 6 replicates. The 96-well cell culture plate was incubated in an incubator for 24 hours. 10 μL CCK8 solution was added to each well of the plate using a repeating pipette. Be careful not to introduce bubbles into the holes as they will interfere with the OD readings. The culture plate was incubated in an incubator for 1-4 hours.
[0080] Before reading the plate, it is important to mix gently on an orbital shaker for 1 minute to ensure an even distribution of color.
[0081] Measure the absorbance at 450 nm using a microplate reader.
[0082] Test results such as Figure 2 As shown, the final target product of the present invention, compound I, showed good inhibitory effects on cell proliferation in 6 tumor cell lines. These cell lines are Hela (IC 50 6.311μM), HepG2 (IC 50 5.013 μM), HGC27 (IC 50 4.887μM), A2780 (IC 50 1.787 μM), A549 (IC 50 6.317μM), ACHN (IC 50 5.887 μM).
[0083] The present invention also provides the use of the indazole-3-carboxylic acid derivatives with antitumor activity in the preparation of antitumor drugs, such as antitumor drugs for treating human cervical cancer, liver cancer, gastric cancer, ovarian cancer, non-small cell lung cancer and renal cell adenocarcinoma.
[0084] It should be noted that:
[0085] (1) In step (1), the organic solvent I is dichloromethane, and may also be ethyl acetate, isopropanol, etc. The organic base I is triethylamine, and may also be methylbutylamide, pyridine, etc.
[0086] (2) In step (2), the organic solvent II is 1,4-dioxane, which can also be replaced by dimethylformamide, tetrahydrofuran, etc. The acidic condition can be replaced by nitric acid, sulfuric acid, etc. in addition to hydrochloric acid.
[0087] (3) In step (3), the organic solvent III may be replaced by DMAC, DMP, etc. in addition to anhydrous DMF; the polypeptide condensation reagent may be replaced by PyBOP, HBTU, etc. in addition to HATU; the organic base II may be replaced by pyridine, hydroxylamine-2-methylpyridine, etc. in addition to triethylamine.
[0088] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.
Claims
1. An indazole-3-carboxylic acid derivative having antitumor activity, characterized in that: The structural formula of the indazole-3-carboxylic acid derivative is shown in Formula I below:
2. A method for preparing an indazole-3-carboxylic acid derivative having antitumor activity as claimed in claim 1, characterized in that: Its synthetic route is as follows: in: Compound 1 is tert-butyl (3-aminophenyl)carbamate; Compound 2 is 1-isocyano-4-(trifluoromethyl)benzene; Compound 3 is tert-butyl (3-(3-(4-(trifluoromethyl)phenyl)ureido)phenyl)carbamate; Compound 4 is 1-(3-aminophenyl)-3-(4-(trifluoromethyl)phenyl)urea; Compound 5 is indazole-3-carboxylic acid; Compound I is N-(3-(3-(4-(trifluoromethyl)phenyl)ureido)phenyl)-1H-indazole-3-carboxamide; It includes the following steps: (1) Compound 1 reacts with compound 2 in an organic solvent I under alkaline conditions with an organic base I as the base. After the reaction is completed, a first post-treatment is performed to obtain compound 3; (2) Under acidic conditions, the compound 3 is cleaved in an organic solvent II to remove the boc group, and then subjected to a second post-treatment to obtain compound 4; (3) Compound 4 and Compound 5 are heated to react in an organic solvent III under the action of a polypeptide condensation reagent and an organic base II. After the reaction is completed, a third post-treatment is performed to obtain Compound I.
3. The preparation method according to claim 2, characterized in that: In the step (1), the organic solvent I is one of dichloromethane, ethyl acetate, and isopropanol; the organic base I is one of triethylamine and pyridine.
4. The preparation method according to claim 2, characterized in that: In the step (1), the reaction temperature of the compound 1 and the compound 2 is 20-30° C. After the reaction is completed, the solvent is evaporated to obtain the compound 3.
5. The preparation method according to claim 2, characterized in that: In the step (2), the organic solvent II is one of 1,4-dioxane and tetrahydrofuran; and the acidic condition is one of hydrochloric acid, nitric acid and sulfuric acid.
6. The preparation method according to claim 2, characterized in that: In the step (2), the second post-treatment method is: filtering and collecting the solid, and drying to obtain compound 4.
7. The preparation method according to claim 2, characterized in that: In the step (3), the organic solvent III is one of anhydrous N,N-dimethylformamide, dimethylacetamide, and dimethylpropionamide; the polypeptide condensation reagent is one of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, benzotriazole-1-yl-oxytripyrrolidinophosphine hexafluorophosphate, and O-benzotriazole-tetramethyluronium hexafluorophosphate; and the organic base II is one of triethylamine and pyridine.
8. The preparation method according to any one of claims 2 to 7, characterized in that: In the step (3), the compound 4 and the polypeptide condensation reagent are added to the organic solvent III, and after sufficient stirring and dissolution, the compound 5 and the organic base II are added; the reaction temperature is controlled at 25-35°C, and after the reaction is completed, the compound I is obtained by a third post-treatment.
9. The preparation method according to claim 2, characterized in that: The third post-treatment method is as follows: adding water at 0°C, filtering after solid precipitation, washing the filter cake with ethyl acrylate and water, and drying the filter cake after washing to obtain compound I.
10. Use of the indazole-3-carboxylic acid derivative with antitumor activity according to claim 1 in the preparation of antitumor drugs for treating human cervical cancer, liver cancer, gastric cancer, ovarian cancer, non-small cell lung cancer and renal cell adenocarcinoma.
